129 related articles for article (PubMed ID: 17477976)
21. A relationship between Alzheimer's disease and type 2 diabetes mellitus through the measurement of serum amyloid-beta autoantibodies.
Kim I; Lee J; Hong HJ; Jung ES; Ku YH; Jeong IK; Cho YM; So I; Park KS; Mook-Jung I
J Alzheimers Dis; 2010; 19(4):1371-6. PubMed ID: 20061608
[TBL] [Abstract][Full Text] [Related]
22. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
23. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele.
Zota V; Nemirovsky A; Baron R; Fisher Y; Selkoe DJ; Altmann DM; Weiner HL; Monsonego A
J Immunol; 2009 Sep; 183(5):3522-30. PubMed ID: 19675171
[TBL] [Abstract][Full Text] [Related]
24. Detection of amyloid beta protein in the urine of Alzheimer's disease patients and healthy individuals.
Takata M; Nakashima M; Takehara T; Baba H; Machida K; Akitake Y; Ono K; Hosokawa M; Takahashi M
Neurosci Lett; 2008 Apr; 435(2):126-30. PubMed ID: 18343031
[TBL] [Abstract][Full Text] [Related]
25. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.
Relkin NR; Szabo P; Adamiak B; Burgut T; Monthe C; Lent RW; Younkin S; Younkin L; Schiff R; Weksler ME
Neurobiol Aging; 2009 Nov; 30(11):1728-36. PubMed ID: 18294736
[TBL] [Abstract][Full Text] [Related]
26. Beta-amyloid pathology in the entorhinal cortex of rats induces memory deficits: implications for Alzheimer's disease.
Sipos E; Kurunczi A; Kasza A; Horváth J; Felszeghy K; Laroche S; Toldi J; Párducz A; Penke B; Penke Z
Neuroscience; 2007 Jun; 147(1):28-36. PubMed ID: 17499931
[TBL] [Abstract][Full Text] [Related]
27. Immune complexes of auto-antibodies against A beta 1-42 peptides patrol cerebrospinal fluid of non-Alzheimer's patients.
Henkel AW; Dittrich PS; Groemer TW; Lemke EA; Klingauf J; Klafki HW; Lewczuk P; Esselmann H; Schwille P; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jun; 12(6):601-10. PubMed ID: 17279093
[TBL] [Abstract][Full Text] [Related]
28. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
30. Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain.
Aoki M; Volkmann I; Tjernberg LO; Winblad B; Bogdanovic N
Neuroreport; 2008 Jul; 19(11):1085-9. PubMed ID: 18596605
[TBL] [Abstract][Full Text] [Related]
31. Chronic psychosocial stress exacerbates impairment of cognition and long-term potentiation in beta-amyloid rat model of Alzheimer's disease.
Srivareerat M; Tran TT; Alzoubi KH; Alkadhi KA
Biol Psychiatry; 2009 Jun; 65(11):918-26. PubMed ID: 18849021
[TBL] [Abstract][Full Text] [Related]
32. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
[TBL] [Abstract][Full Text] [Related]
33. Natural human antibodies to amyloid beta peptide.
Szabo P; Relkin N; Weksler ME
Autoimmun Rev; 2008 Jun; 7(6):415-20. PubMed ID: 18558354
[TBL] [Abstract][Full Text] [Related]
34. Plasma biomarkers of Alzheimer's disease.
Kawarabayashi T; Shoji M
Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
[TBL] [Abstract][Full Text] [Related]
35. Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta.
Balakrishnan K; Andrei-Selmer LC; Selmer T; Bacher M; Dodel R
J Alzheimers Dis; 2010; 20(1):135-43. PubMed ID: 20164596
[TBL] [Abstract][Full Text] [Related]
36. Specificity and sensitivity of the Abeta oligomer ELISA.
Klaver AC; Patrias LM; Finke JM; Loeffler DA
J Neurosci Methods; 2011 Feb; 195(2):249-54. PubMed ID: 21163305
[TBL] [Abstract][Full Text] [Related]
37. Cholinesterase inhibitor use is associated with increased plasma levels of anti-Aβ 1-42 antibodies in Alzheimer's disease patients.
Conti E; Galimberti G; Tremolizzo L; Masetto A; Cereda D; Zanchi C; Piazza F; Casati M; Isella V; Appollonio I; Ferrarese C
Neurosci Lett; 2010 Dec; 486(3):193-6. PubMed ID: 20869427
[TBL] [Abstract][Full Text] [Related]
38. ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.
Klaver AC; Coffey MP; Smith LM; Bennett DA; Finke JM; Dang L; Loeffler DA
J Neuroinflammation; 2011 Aug; 8():93. PubMed ID: 21827691
[TBL] [Abstract][Full Text] [Related]
39. Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type.
Myagkova MA; Gavrilova SI; Lermontova NN; Kalyn YB; Selezneva ND; Zharikov GA; Kolykhalov IV; Abramenko TV; Serkova TP; Bachurin SO
Bull Exp Biol Med; 2001 Feb; 131(2):127-9. PubMed ID: 11391392
[TBL] [Abstract][Full Text] [Related]
40. Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients.
Wilhelm KR; Yanamandra K; Gruden MA; Zamotin V; Malisauskas M; Casaite V; Darinskas A; Forsgren L; Morozova-Roche LA
Eur J Neurol; 2007 Mar; 14(3):327-34. PubMed ID: 17355556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
